{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:10:08Z","timestamp":1760148608050,"version":"build-2065373602"},"reference-count":14,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health\u2014Current research IRCCS"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Objectives: Monoclonal antibodies (mAbs) have proven to be a valuable tool against COVID-19, mostly among subjects with risk factors for progression to severe illness. Tixagevimab\/cilgavimab (TIX\/CIL), a combination of two Fc-modified human monoclonal antibodies, has been recently approved to be employed as early treatment. Methods: Two groups of immunocompromised patients exposed to different early treatments (i.e., TIX\/CIL vs. other mAbs [casirivimab\/imdevimab, bamlanivimab\/etesevimab, sotrovimab]) were compared in terms of clinical outcomes (hospitalisation and mortality within 14 days from administration) and time to the negativity of nasal swabs. We used either Pearson\u2019s chi-square or Fisher\u2019s exact test for categorical variables, whereas the Wilcoxon rank\u2013sum test was employed for continuous ones. Kaplan\u2013Meier curves were produced to compare the time to nasopharyngeal swab negativity. Results: Early treatment with TIX\/CIL was administered to 19 immunocompromised patients, while 89 patients received other mAbs. Most of them were solid organ transplant recipients or suffering from hematologic or solid malignancies. Overall, no significant difference was observed between the two groups regarding clinical outcomes. In the TIX\/CIL group, one patient (1\/19, 5.3%), who was admitted to the emergency room within the first 14 days from treatment and was hospitalised due to COVID-19 progression, died. Regarding the time to nasal swab negativity, no significant difference (p = 0.088) emerged. Conclusions: Early treatment of SARS-CoV-2 infection with TIX\/CIL showed favourable outcomes in a small group of immunocompromised patients, reporting no significant difference compared to similar patients treated with other mAbs.<\/jats:p>","DOI":"10.3390\/biomedicines11061540","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T16:10:53Z","timestamp":1685203853000},"page":"1540","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab\/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-9579","authenticated-orcid":false,"given":"Andrea","family":"Lombardi","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"},{"name":"Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, 20122 Milan, Italy"},{"name":"Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Viero","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Villa","sequence":"additional","affiliation":[{"name":"Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4988-0427","authenticated-orcid":false,"given":"Simona","family":"Biscarini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1386-6180","authenticated-orcid":false,"given":"Emanuele","family":"Palomba","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Azzar\u00e0","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Iannotti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Mariani","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Genovese","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Tomasello","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tonizzo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Fava","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia Grazia","family":"Valzano","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4661-6471","authenticated-orcid":false,"given":"Letizia Corinna","family":"Morlacchi","sequence":"additional","affiliation":[{"name":"Respiratory Unit and Cystic Fibrosis Adult Center, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Francesca","family":"Donato","sequence":"additional","affiliation":[{"name":"A.M. & A. Migliavacca Center for Liver Disease, Division of Gastroenterology and Hepatology, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Castellano","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis, and Renal Transplantation, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona","family":"Cassin","sequence":"additional","affiliation":[{"name":"Hematology Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0717-9096","authenticated-orcid":false,"given":"Maria","family":"Carrabba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Adult Primary Immunodeficiencies Centre, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Muscatello","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-4794","authenticated-orcid":false,"given":"Andrea","family":"Gori","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"},{"name":"Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, 20122 Milan, Italy"},{"name":"Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Bandera","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"},{"name":"Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, 20122 Milan, Italy"},{"name":"Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1038\/s41598-022-22431-6","article-title":"Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: A Bayesian network meta-analysis","volume":"12","author":"McConnell","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab\u2013Cilgavimab) for Prevention of COVID-19","volume":"386","author":"Levin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"abl8124","DOI":"10.1126\/scitranslmed.abl8124","article-title":"The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans","volume":"14","author":"Loo","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S2213-2600(22)00215-6","article-title":"Tixagevimab\u2013cilgavimab for treatment of patients hospitalised with COVID-19: A randomised, double-blind, phase 3 trial","volume":"10","author":"Ginde","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab\u2013cilgavimab for early outpatient treatment of COVID-19 (TACKLE): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Montgomery","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Biscarini, S., Villa, S., Genovese, C., Tomasello, M., Tonizzo, A., Fava, M., Iannotti, N., Bolis, M., Mariani, B., and Valzano, A.G. (2022). Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study. Biomedicines, 10.","DOI":"10.3390\/biomedicines10082002"},{"key":"ref_7","unstructured":"AIFA (2022, December 15). AIFA Evusheld Trattamento, Available online: https:\/\/www.aifa.gov.it\/-\/aifa-autorizza-l-utilizzo-terapeutico-del-monoclonale-evusheld-per-il-trattamento-precoce-del-covid-19-in-soggetti-a-rischio-di-progressione."},{"key":"ref_8","unstructured":"ECDC (2022, December 15). ECDC VOCs Monitoring 2022. Available online: https:\/\/www.ecdc.europa.eu\/en\/covid-19\/country-overviews."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1654.e1","DOI":"10.1016\/j.cmi.2022.07.015","article-title":"Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1111\/ajt.17128","article-title":"Tixagevimab\/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave","volume":"22","author":"Morena","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_11","first-page":"22","article-title":"Omicron sublineage BQ.1.1 resistance to monoclonal antibodies","volume":"214","author":"Arora","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41409-022-01894-1","article-title":"Tixagevimab\/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases","volume":"58","author":"Otiniano","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Akinosoglou, K., Rigopoulos, E.A., Kaiafa, G., Daios, S., Karlafti, E., Ztriva, E., Polychronopoulos, G., Gogos, C., and Savopoulos, C. (2023). Tixagevimab\/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience. Viruses, 15.","DOI":"10.3390\/v15010118"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/6\/1540\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:42:39Z","timestamp":1760125359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/6\/1540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["biomedicines11061540"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines11061540","relation":{},"ISSN":["2227-9059"],"issn-type":[{"type":"electronic","value":"2227-9059"}],"subject":[],"published":{"date-parts":[[2023,5,26]]}}}